0DRV Stock Overview
A life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
ArcticZymes Technologies ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 16.90 |
| 52 Week High | NOK 26.40 |
| 52 Week Low | NOK 12.96 |
| Beta | 0.75 |
| 1 Month Change | 16.55% |
| 3 Month Change | 19.86% |
| 1 Year Change | n/a |
| 3 Year Change | -75.20% |
| 5 Year Change | n/a |
| Change since IPO | 297.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0DRV | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -0.3% | 5.1% | 0.9% |
| 1Y | n/a | -15.3% | 0.3% |
Return vs Industry: Insufficient data to determine how 0DRV performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0DRV performed against the UK Market.
Price Volatility
| 0DRV volatility | |
|---|---|
| 0DRV Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0DRV's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0DRV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 53 | Michael Akoh | www.arcticzymes.com |
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; double-strand specific DNases and derived kits for the removal of double stranded DNA; DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. It serves the molecular tools research and diagnostics, and biomanufacturing markets.
ArcticZymes Technologies ASA Fundamentals Summary
| 0DRV fundamental statistics | |
|---|---|
| Market cap | NOK 832.46m |
| Earnings (TTM) | NOK 7.57m |
| Revenue (TTM) | NOK 108.11m |
109.9x
P/E Ratio7.7x
P/S RatioIs 0DRV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0DRV income statement (TTM) | |
|---|---|
| Revenue | NOK 108.11m |
| Cost of Revenue | NOK 5.98m |
| Gross Profit | NOK 102.12m |
| Other Expenses | NOK 94.55m |
| Earnings | NOK 7.57m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | 0.15 |
| Gross Margin | 94.47% |
| Net Profit Margin | 7.00% |
| Debt/Equity Ratio | 0% |
How did 0DRV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 21:08 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ArcticZymes Technologies ASA is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hans Bohn | Beringer Finance AB |
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |
| Espen Jørgensen | DNB Markets |